Study ADI-PEG 20 Plus Pembrolizumab in Advanced Solid Cancers

Phase 1B Study of ADI-PEG 20 Plus Pembrolizumab in Advanced Solid Cancers

NCT03254732•Polaris Group

Summary

This is a phase 1b, open label trial of ADI-PEG 20 (36 mg/m2) weekly in combination with pembrolizumab (1 and 2 mg/kg or 200 mg) every three weeks. Assessment of safety and tolerability of drug combination

Detailed Description

This is an open-label, phase 1b trial of ADI-PEG 20 in combination with pembrolizumab in subjects with advanced cancers. Dose escalation will occur using a 3 + 3 + 3 design. The first subject in a dose escalation cohort must have had treatment with ADI-PEG 20 + pembrolizumab with a week of follow up) before the next 2 subjects are enrolled. Thus subjects 2 and 3 may be enrolled on day 8 if there is no dose limiting toxicity (DLT) in subject 1. No additional delay is required between treating subjects 4 to 6 or 7 to 9 in an expanded cohort. Before proceeding to the next cohort dose level, the first 3 eligible subjects in each cohort will have received at least 21 days of treatment (i.e. at least 2 of the expected 3 doses of ADI-PEG 20 + one dose of pembrolizumab).

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. Histologically confirmed diagnosis of advanced solid tumor.
•2. Prior failure of a systemic treatment approved by the health authority in the country where the study will be enrolling. Such subjects may also have been treated with radiotherapy, local therapy or surgery.
•3. Measurable disease using RECIST 1.1 criteria.
•4. Age ≥ 18 years.

Exclusion Criteria

•1. Subjects with history of another primary cancer, including co-existent second malignancy, with the exception of: a) curatively resected non-melanoma skin cancer; b) curatively treated cervical carcinoma in situ; or c) other primary solid tumor with no known active disease present or in the opinion of the investigator will not affect patient outcome.
•2. Subjects who had been treated with ADI-PEG 20 previously.
•3. History of seizure disorder not related to underlying cancer.
•4. Known allergy to pegylated compounds.
•5. Known allergy to E. coli drug products (such as GMCSF).

Locations (1)

Facility National Cheng Kung University

Tainan, Taiwan

Key Dates

Start Date

July 14, 2017

Primary Completion Date

May 7, 2019

Completion Date

February 25, 2020

Last Updated

April 27, 2022

Enrollment

ACTUAL participants

Conditions

Advanced Solid Cancers

Interventions

ADI PEG20

DRUG

Pembrolizumab

DRUG

A Clinical Trial to Test if the Investigational Drug BNT329 is Safe and Potentially Beneficial for People With Advanced Solid Tumors Known to Express the Tumor Marker CA19-9

NCT07186842

Advanced Solid Cancers

View study

COMPLETEDPHASE1

An Investigational Immunotherapy Study of BMS-986301 Alone or in Combination With Nivolumab, and Ipilimumab in Participants With Advanced Solid Cancers

NCT03956680

Advanced Solid Cancers

View study

TERMINATEDPHASE1/PHASE2

A Study of BMS-863233 in Patients With Advanced and/or Metastatic Solid Tumors

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: April 27, 2022Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions